Subject(s)
COVID-19 , Pulmonary Embolism , Respiratory Distress Syndrome , Humans , Proteoglycans , SARS-CoV-2Subject(s)
COVID-19 , Pneumothorax , Humans , Pneumothorax/diagnostic imaging , Risk Factors , SARS-CoV-2 , Severity of Illness IndexSubject(s)
C-Reactive Protein , Interleukin-6 , Bilirubin , Ferritins , Humans , L-Lactate Dehydrogenase , Lymphocytes , Organ Dysfunction ScoresABSTRACT
Background and Objectives: SARS-CoV-2-induced ARDS is a new entity that should be characterized as it appears to be different from standard ARDS. Hypernatremia is a biological alteration that seems to occur very often in this population without any clear cause. The present study aims to clarify the possible causes of hypernatremia and evaluate its impact on patient outcome. Patients and Methods: We conducted a retrospective one-day prevalence study in 2 intensive care units, which only treated COVID-19 patients with moderate to severe ARDS. We measured blood and urine electrolytes in all the patients. Patients with chronic renal failure or renal replacement therapy were excluded from the study. Hypernatremia was defined as plasma sodium levels above 145 mmol/L. Results: Inclusion criteria were met in 17 out of 24 patients. Hypernatremia was present in 52% patients. All had a natriuresis higher than 20 mmol/L and a urine osmolality above 600 mOsm/L. Hypernatremia was acquired in ICU as all the patients had a normal serum sodium level at admission. Conclusion: The incidence of hypernatremia was elevated and appears to be linked to significant insensible water losses. This should trigger us to optimize the maintenance fluid therapy in critically ill patients with SARS-CoV-2-induced ARDS.
ABSTRACT
Suspicion threshold for opportunistic coinfections should be lowered in severe COVID-19. Serum CMV polymerase chain reaction and colonoscopy should be discussed in presence of persistent digestive disturbances.